Article
Knockdown of ANLN inhibits the progression of lung adenocarcinoma via pyroptosis activation
3 Aug 2023
Abstract excerpt
Significant advancements have been achieved in the area of molecular targeted therapy for lung adenocarcinoma (LUAD). However, the complex molecular patterns and high heterogeneity of LUAD confine the efficacy of these therapies to a specific subset of patients; therefore, it is necessary to explore novel targets for LUAD treatment. The expression levels of anillin (ANLN) in LUAD were analyzed using the Gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
